A novel biparatopic synthetic TCR and antigen receptor called STAR-T targeting LILRB4 completed a Phase I clinical trial for R/R AML (NCT05518357, results not yet available) [144]. This evidence concerns the gene LILRB4 and acute myeloid leukemia.